Publication Name	World Journal of Gastrointestinal Oncology
Manuscript ID	93471
Country	China

Received	2024-02-28 01:58
Peer-Review Started	2024-03-01 00:17
To Make the First Decision
Return for Revision	2024-05-08 03:24
Revised	2024-05-11 15:29
Second Decision	2024-06-11 02:42
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2024-06-11 07:46
Articles in Press	2024-06-11 07:46
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2024-07-31 06:06
Publish the Manuscript Online	2024-09-26 10:17

ISSN	1948-5204 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Oncology
Manuscript Type	Editorial
Article Title	Unresectable hepatocellular carcinoma: Transarterial chemoembolization combined with lenvatinib in combination with programmed death-1 inhibition is a possible approach
Manuscript Source	Invited Manuscript
All Author List	Fei-Yu Zhao, Dong-Yu Wang and Nian-Song Qian
ORCID	Author(s) ORCID Number Nian-Song Qian http://orcid.org/0000-0002-3297-4294
Funding Agency and Grant Number
Corresponding Author	Nian-Song Qian, MD, Chief Physician, Senior Department of Thoracic Oncology, Respiratory and Critical Care Medicine, The Eighth Medical Center of People’s Liberation Army General Hospital, No. 28 Fuxing Road, Beijing 100091, China. qianniansong1@163.com
Key Words	Transarterial chemoembolization; Programmed death 1; Lenvatinib; Hepatocellular carcinoma
Core Tip	This article focuses on the efficacy of transarterial chemoembolization combined with lenvatinib in combination with programmed death 1 inhibitors in patients with advanced hepatocellular carcinoma. Although transarterial chemoembolization as well as lenvatinib in combination with programmed death 1 have both achieved some efficacy in advanced hepatocellular carcinoma, more clinical evidence is needed on the efficacy of all three combinations.
Publish Date	2024-09-26 10:17
Citation	<p>Zhao FY, Wang DY, Qian NS. Unresectable hepatocellular carcinoma: Transarterial chemoembolization combined with lenvatinib in combination with programmed death-1 inhibition is a possible approach. <i>World J Gastrointest Oncol</i> 2024; 16(10): 4042-4044</p>
URL	https://www.wjgnet.com/1948-5204/full/v16/i10/4042.htm
DOI	https://dx.doi.org/10.4251/wjgo.v16.i10.4042

Full Article (PDF)	WJGO-16-4042-with-cover.pdf
Manuscript File	93471_Auto_Edited-YJP.docx
Answering Reviewers	93471-answering-reviewers.pdf
Audio Core Tip	93471-audio.m4a
Conflict-of-Interest Disclosure Form	93471-conflict-of-interest-statement.pdf
Copyright License Agreement	93471-copyright-assignment.pdf
Non-Native Speakers of English Editing Certificate	93471-non-native-speakers.pdf
Peer-review Report	93471-peer-reviews.pdf
Scientific Misconduct Check	93471-scientific-misconduct-check.png
Scientific Editor Work List	93471-scientific-editor-work-list.pdf
CrossCheck Report	93471-crosscheck-report.pdf